Alpine Select AG (XSWX:ALPN) Net Change in Cash : CHF-7.41 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Alpine Select AG Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Alpine Select AG's Net Change in Cash for the six months ended in Dec. 2023 was CHF-11.75 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-7.41 Mil.

Alpine Select AG Net Change in Cash Historical Data

The historical data trend for Alpine Select AG's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Select AG Net Change in Cash Chart

Alpine Select AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

18.88

-13.91

-12.91

18.92

-7.41

Alpine Select AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															-6.06	-6.42	25.34	4.34	-11.75

Alpine Select AG Net Change in Cash Calculation

Alpine Select AG's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	3.913	+	27.986	+	-39.27	+	-0.034
	=	-7.41

Alpine Select AG's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 3.585 + 14.109 + -29.407 + -0.035

= -11.75

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-7.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpine Select AG Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Alpine Select AG's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpine Select AG (XSWX:ALPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Alpine Select AG (XSWX:ALPN) » Definitions » Net Change in Cash

Comparable Companies

XSWX:NBEN XSWX:CPEN XSWX:GAM XSWX:EEII XSWX:PEHN XSWX:BBN BLK BX KKR OSTO:INVE A APO TSX:BN AMP BK OSTO:EQT XSWX:PGHN LSE:III TROW BOM:543940 ARES

Traded in Other Exchanges

N/A

Address

Gotthardstrasse 31, Zug, CHE, CH-6300

Website

https://www.alpine-select.ch

Alpine Select AG is an investment company that offers institutional and individual investors the key benefit of investing into a diversified alternative investment portfolio with core investment strategies: discount-, risk-arbitrage, tactical exploitation of under-researched companies/situations, short-term opportunities, liquid hedge funds and digital assets. The company's objective is to obtain capital appreciation from investments in core investment strategies: discount-, risk-arbitrage, tactical exploitation of under-researched companies/situations, short term opportunities, liquid hedge funds and digital assets.

Alpine Select AG (XSWX:ALPN) Headlines

From GuruFocus

Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
By Business Wire • 11-15-2023

Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
By Business Wire • 11-07-2023

Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
By Business Wire • 08-14-2023

Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
By Business Wire Business Wire • 11-22-2022

Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
By Business Wire • 10-04-2023

Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
By Business Wire Business Wire • 11-07-2022

Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference
By Business Wire Business Wire • 02-09-2023

Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
By Business Wire • 08-30-2023

Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences
By Business Wire Business Wire • 10-26-2022

Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
By Business Wire • 09-12-2023